(Q44583432)

4 December 2017

1 reference

title

Antiviral T-cell responses and therapy in chronic hepatitis B. (English)

1 reference

4 December 2017

Nadia Alatrakchi

1

1 reference

4 December 2017

Margaret James Koziel

series ordinal

2

1 reference

4 December 2017

publication date

1 October 2003

1 reference

4 December 2017

published in

Journal of Hepatology

1 reference

4 December 2017

volume

39

1 reference

4 December 2017

issue

4

1 reference

4 December 2017

page(s)

631-634

1 reference

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Long-lasting memory T cell responses following self-limited acute hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Immunization against hepatitis B through adoptive transfer of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Interleukin-12 in the treatment of chronic hepatitis B and C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900398-2

7 January 2021

10.1016/S0168-8278(03)00398-2

Identifiers

DOI

1 reference

release_vt4qlpa7lzc7npcsllqzbq4m7a

4 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vt4qlpa7lzc7npcsllqzbq4m7a

24 November 2022

mapped directly with Wikidata item

1 reference